CorMedix Inc. (CRMD) is priced at $7.93 after the most recent trading session. At the very opening of the session, the stock price was $9.46 and reached a high price of $9.46, prior to closing the session it reached the value of $9.37. The stock touched a low price of $7.851.
Recently in News on April 14, 2021, CorMedix Has Meeting With FDA on DefenCath Catheter Lock Solution NDA. CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has met with the US Food and Drug Administration (FDA) to discuss proposed resolutions for the deficiencies identified in the Complete Response Letter (CRL) to CorMedix and the Post-Application Action Letter received by the third-party manufacturer (CMO) from FDA for the New Drug Application (NDA) for DefenCath™ (taurolidine/heparin catheter lock solution). Representatives from both CorMedix and the CMO participated in the meeting with FDA to ensure that there is alignment on addressing the Agency’s concerns. You can read further details here
CorMedix Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $18.80 on 02/19/21, with the lowest value was $6.41 for the same time period, recorded on 03/05/21.
CorMedix Inc. (CRMD) full year performance was 102.30%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CorMedix Inc. shares are logging -57.82% during the 52-week period from high price, and 128.53% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.47 and $18.80.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1891379 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the CorMedix Inc. (CRMD) recorded performance in the market was 6.73%, having the revenues showcasing -9.37% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 311.01M, as it employees total of 35 workers.
Market experts do have their say about CorMedix Inc. (CRMD)
During the last month, 0 analysts gave the CorMedix Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 9.70, with a change in the price was noted +1.91. In a similar fashion, CorMedix Inc. posted a movement of +31.73% for the period of last 100 days, recording 989,427 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CRMD is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of CorMedix Inc. (CRMD)
Raw Stochastic average of CorMedix Inc. in the period of last 50 days is set at 12.27%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 2.87%. In the last 20 days, the company’s Stochastic %K was 33.31% and its Stochastic %D was recorded 46.67%.
Bearing in mind the latest performance of CorMedix Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 6.73%. Additionally, trading for the stock in the period of the last six months notably improved by 33.95%, alongside a boost of 102.30% for the period of the last 12 months. The shares increased approximately by -18.83% in the 7-day charts and went down by -14.46% in the period of the last 30 days. Common stock shares were lifted by -9.37% during last recorded quarter.